Iannone Robert 4
4 · Jazz Pharmaceuticals plc · Filed Mar 7, 2025
Insider Transaction Report
Form 4
Iannone Robert
EVP, Global Head of R&D & CMO
Transactions
- Disposition to Issuer
Ordinary Shares
2025-03-05$138.95/sh−5,239$727,959→ 89,104 total - Sale
Ordinary Shares
2025-03-07$138.21/sh−5,532$764,578→ 83,572 total - Sale
Ordinary Shares
2025-03-07$140.00/sh−1,548$216,720→ 82,024 total
Footnotes (3)
- [F1]Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
- [F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F3]Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.19 to $138.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.